Sign in

You're signed outSign in or to get full access.

Alice Avanian

Supervisory Analyst and Vice President at Piper Sandler

Alice Avanian is a Supervisory Analyst and Vice President at Piper Sandler, specializing in biotechnology and healthcare research with a demonstrated involvement in covering companies like Alkermes (ALKS). She actively participates in earnings calls, such as the ALKS Q4 2025 call where she represented Piper Sandler, though specific performance metrics like success rates or rankings on platforms such as TipRanks are not publicly detailed. Avanian joined Piper Sandler in April 2022 after holding similar roles at Goldman Sachs, Cantor Fitzgerald, Leerink Partners LLC, and Cowen & Co., building a robust career in equity research and analysis. She holds a CFA charter, a Bachelor’s Degree in Management/Marketing from New York University, and an MBA in Finance from NYU Stern School of Business, along with leadership experience chairing the Boston Security Analysts Society.

Alice Avanian's questions to Alkermes (ALKS) leadership

Question · Q4 2025

Alice Avanian, on behalf of David Amsellem, asked about Alkermes' strategy for the LUMRYZ field force, considering a new market entrant by year-end, and whether expansion would focus on breadth or depth.

Answer

Todd Nichols, Chief Commercial Officer of Alkermes, stated the current sales force is 'right-sized' to target oxybate-eligible patients and a dynamic segment of cycling patients. He noted encouraging trends and recent investments. LUMRYZ is seen as uniquely positioned with strong payer access (over 90% commercial), and they will monitor competitive entrants.

Ask follow-up questions

Fintool

Fintool can predict Alkermes logo ALKS's earnings beat/miss a week before the call